Business Description
uniQure NV
ISIN : NL0010696654
Description
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.46 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 0.67 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.49 | |||||
| Beneish M-Score | -3.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -26.7 | |||||
| 3-Year EBITDA Growth Rate | -23 | |||||
| 3-Year EPS without NRI Growth Rate | -36.2 | |||||
| 3-Year FCF Growth Rate | 0.4 | |||||
| 3-Year Book Growth Rate | -7.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.85 | |||||
| 9-Day RSI | 40.95 | |||||
| 14-Day RSI | 41.63 | |||||
| 6-1 Month Momentum % | -19.51 | |||||
| 12-1 Month Momentum % | -73.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.85 | |||||
| Quick Ratio | 8.68 | |||||
| Cash Ratio | 8.39 | |||||
| Days Inventory | 280.1 | |||||
| Days Sales Outstanding | 1454.03 | |||||
| Days Payable | 221.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.2 | |||||
| Shareholder Yield % | -0.33 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 13.98 | |||||
| Operating Margin % | -1785.46 | |||||
| Net Margin % | -1947.09 | |||||
| FCF Margin % | -964.06 | |||||
| ROE % | -89.75 | |||||
| ROA % | -38.73 | |||||
| ROIC % | -103.3 | |||||
| ROC (Joel Greenblatt) % | -224.62 | |||||
| ROCE % | -36.51 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 13.73 | |||||
| PB Ratio | 1.05 | |||||
| Price-to-Tangible-Book | 1.8 | |||||
| EV-to-EBIT | 0.99 | |||||
| EV-to-Forward-EBIT | -14.87 | |||||
| EV-to-EBITDA | 1.03 | |||||
| EV-to-Forward-EBITDA | -2.66 | |||||
| EV-to-Revenue | -16.5 | |||||
| EV-to-Forward-Revenue | 2.51 | |||||
| EV-to-FCF | 1.71 | |||||
| Price-to-Median-PS-Value | 0.4 | |||||
| Price-to-Net-Current-Asset-Value | 7.9 | |||||
| Earnings Yield (Greenblatt) % | 101.01 | |||||
| FCF Yield % | -70.18 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers